Clinical trials: Human Brain and Cognition
Dementia
Preventing Medication Mismanagement in People Living With Dementia
The purpose of this research is to learn whether the HiDO-ALZ device can improve medication compliance and health outcomes in participants with dementia that need to take daily medication.
- Trial name
- NCT07600684
- Testing
- HiDO HomeCareSystem
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- HiDO Technologies
Huntington Disease
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of MBF-015 in Huntington's Disease Patients
This is a Phase IIa (proof of concept), single center clinical trial to evaluate the safety and efficacy of daily MBF-015 oral treatment during 28 days in Huntington's Disease patients on top of standard of care.
- Trial name
- NCT06469853
- Testing
- MBF-015 16 mg oral capsules
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Medibiofarma S.L.
Alzheimer's Type Dementia
A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia
The purpose of this study is to compare 23 mg donepezil sustained release (SR) to the currently marketed formulation of 10 mg donepezil immediate release (IR) in patients with severe Alzheimer's disease.
- Trial name
- NCT01276353
- Testing
- E2020
- Where
- 11 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Eisai Inc.
Alzheimer Disease, Mild Cognitive Impairment
Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey
There is a major unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and dementia.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Decline
- Trial name
- QUIP II (NCT06025877)
- Testing
- PrecivityAD2(TM) blood test
- Where
- 9 sites in United States
- Volunteers
- 400 people
- Sponsor
- C2N Diagnostics
Alzheimer Disease, Dementia
A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)
The main goals of this study are to further determine whether the study drug donanemab is safe and effective in participants with Alzheimer's disease and to validate neuropsychological assessments administered over…
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- NCT04640077
- Testing
- No Intervention, donanemab
- Where
- 27 sites in United States, Canada
- Volunteers
- 95 people
- Sponsor
- Eli Lilly and Company
Cognitive Symptoms
Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment
This study is designed to investigate the efficacy and safety of rivastigmine compared with placebo in patients with mild cognitive impairment (MCI).
- Trial name
- NCT00134953
- Testing
- Rivastigmine
- Volunteers
- 24 people
- Sponsor
- Novartis
Alzheimer Disease, Cognitive Impairment
Multi-Center Study of Sensory Stimulation to Improve Brain Function
The Overture Study is a randomized, controlled, single-blind multi-center clinical trial using the GammaSense Stimulation system to study safety, tolerability, and efficacy in people with mild to moderate cognitive impairment.
- Conditions
- Alzheimer Disease, Cognitive Impairment, Mild Cognitive Impairment, Dementia Alzheimers
- Trial name
- Overture (NCT03556280)
- Testing
- GammaSense Stimulation System (Active Settings)
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Cognito Therapeutics, Inc.
Cognitive Change, Sleep Deprivation
Sleep Deprivation Study
The purpose of this study is to evaluate the measures of brain function, both neurophysiological (event-related potentials (ERPs) and functional (cognitive assessments), in response to sleep deprivation.
- Conditions
- Cognitive Change, Sleep Deprivation, Caffeine
- Trial name
- NCT05560620
- Testing
- Sleep Deprivation, Caffeine, No Caffeine
- Where
- Canada
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- NeuroCatch Inc.
Stroke
Arm Motor Rehabilitation, Entertainment and Cognition System for the Elderly
The research project is intended to provide information pertaining to the feasibility of the BrightArm Compact robotic rehabilitation system for patients early sub-acute post Cerebral Vascular Accident.
- Trial name
- NCT04252170
- Testing
- Rehabilitation Therapy, Experimental on the BrightArm Compact device
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Bright Cloud International Corp
Parkinson's Disease, PD
iPACES v3 MCI NIA Protocol Copied for iPACES v4 PD NINDS
The primary purpose of this study is to attempt to replicate and extend promising pilot findings regarding the cognitive benefits of in-home neuro-exergaming with iPACES (interactive Physical and Cognitive Exercise System v3) for…
- Conditions
- Parkinson's Disease, PD, Mild Cognitive Impairment, MCI
- Trial name
- iPACES-PD (NCT05810454)
- Testing
- iPACES (interactive Physical and Cognitive Exercise System), PACE (Physical and Cognitive Exercise)
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- iPACES LLC
Alzheimer's Disease
Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease
This study will investigate the ability of ST101 to improve memory in people with Alzheimer's disease who currently receive 10 mg Aricept® (donepezil) per day. This study also will examine the safety and tolerability of the drug.
- Trial name
- NCT00842816
- Testing
- ST101
- Where
- 30 sites in United States, Canada
- Volunteers
- 210 people
- Sponsor
- Sonexa Therapeutics, Inc.
Huntington's Disease
A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance and functioning in participants with HD.
- Trial name
- NCT05107128
- Testing
- SAGE-718
- Where
- 49 sites in United States, Australia and 2 more
- Volunteers
- 189 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Memory Disorders, Alzheimer Disease
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
The proposed study is designed to evaluate the performance of the COGNISION™ System as a tool to assist physicians in diagnosing Alzheimer's Disease (AD) in real-world clinical settings.
- Conditions
- Memory Disorders, Alzheimer Disease, Dementia, Cognitive Impairment
- Trial name
- COGNISION™ (NCT00938665)
- Testing
- COGNISION™ System
- Where
- 7 sites in United States
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Neuronetrix, Inc.
Huntington Disease
The Safety and Tolerability Study With ER2001 Intravenous Injection Repetitive Treatment in Adults With Early Manifest Huntington's Disease.
This is an open label, dose escalation clinic trial to evaluate safety, tolerability and pharmacokinetics with ER2001 Intravenous Injection repetitive treatment in Huntington's Disease patients who Completed Study…
- Trial name
- NCT07344519
- Testing
- ER2001 injection
- Where
- China
- Volunteers
- 8 people
- Sponsor
- ExoRNA Bioscience
Traumatic Brain Injury
Pilot, Proof-of-Concept Study of Sublingual Tizanidine in Children With Chronic Traumatic Brain Injury (TBI)
Nightly administration of a unique, sublingual (under the tongue) formulation of tizanidine, a known anti-spasticity medication, has been shown in a previous study to improve sleep and next-day functioning in CP (cerebral palsy)…
- Trial name
- NCT00287157
- Testing
- Sublingual Tizanidine HCl
- Where
- Israel
- Volunteers
- 5 people
- Sponsor
- Teva GTC
Postcomatose Unawareness State, Minimally Conscious State
Eye Tracking Technology in the Diagnosis of Neurological Patients
Demonstrating that diagnostics of the state of consciousness and cognitive functions of patients with consciousness disorders performed using C-Eye X (based on eye-tracking technology) allows a more objective assessment of state…
- Conditions
- Postcomatose Unawareness State, Minimally Conscious State, Vegetative State, Disorder of Consciousness
- Trial name
- NCT05536921
- Where
- 5 sites in Poland
- Volunteers
- 90 people
- Sponsor
- AssisTech Sp. z o.o.
Huntington Disease
Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease
This is a double-blind, placebo-controlled 2-period 10-week treatment within-subject crossover study of neflamapimod in early-stage Huntington disease (HD).
- Trial name
- NCT03980938
- Testing
- neflamapimod
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- EIP Pharma Inc
Alzheimer's Disease
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose.
- Trial name
- REFLECT-2 (NCT00348309)
- Testing
- Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg, Donepezil
- Where
- 249 sites in United States, Argentina and 17 more
- Volunteers
- 1,496 people
- Sponsor
- GlaxoSmithKline
Phenylketonuria
Kuvan®'s Effect on the Cognition of Children With Phenylketonuria
The study is a single-cohort, interventional, open-label trial to evaluate long-term neurocognitive (NC) outcomes in children aged 4 to 5 years with phenylketonuria (PKU) treated with Kuvan® and Phenylalanine-restricted diet over…
- Trial name
- KOGNITO (NCT01965912)
- Testing
- Kuvan®
- Where
- 12 sites in Germany, Italy and 2 more
- Volunteers
- 34 people
- Sponsor
- BioMarin Pharmaceutical
Mild Cognitive Impairment and Dementia
UK Validation of the Automated "AcceXible" Speech Analysis Software
Dementia, especially dementia caused by Alzheimer's disease, is considered one of the most severe health problems of our time. It is currently known that the disease begins many years before clinical symptoms appear.
- Trial name
- NCT05534958
- Testing
- Accexible
- Where
- United Kingdom
- Volunteers
- 221 people
- Sponsor
- Accexible